Foamix Receives a New U.S. Patent for Its Emollient and Aqueous Foam Technology
The Patent Covers Foams with Urea, Lactic Acid, Salicylic Acid and Penetration Enhancers
Rehovot, Israel, May 01, 2010 --(PR.com)-- Foamix Ltd., a leading developer of topical products, which can be used for dermatological, gynecological and ophthalmic applications, today announced that the United States Patent Office has granted the company a new patent on its Emollient and Aqueous Foam technology platforms.
United States Patent No. 7,700,076, entitled “Penetrating pharmaceutical foam” covers unique emollient foam compositions and aqueous foam compositions that can be used to deliver a wide range of actives having activity against many diseases and disorders.
"Foamix continually strives to strengthen and expand its intellectual property position, which is a key aspect to our business and competitive position. The grant of this U.S. patent is the result of extensive ongoing efforts to develop a stream of innovative products and technologies for the dermatology and gynecology markets that provide enhanced efficacy and consumer satisfaction," said Dr. Dov Tamarkin, CEO of Foamix.
The patent claims foam compositions comprising urea, alpha-hydroxy acids (such as lactic acid and glycolic acid) and beta-hydroxy acids, e.g., salicylic acid, which are keratolytic).
The granted claims are further directed to foam compositions that contain skin penetration enhancers, including inter alia propylene glycol, glycerol, dimethyl isosorbide, and certain polyethylene glycol PEG polymers. The claims also cover a variety of drugs that can additionally be incorporated in such compositions, including antibacterial agents, antifungals, antiviral agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators.
About Foamix Ltd.
Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical foam and Oil Gel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.
To date, Foamix has twenty two issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.
For additional information please see: www.foamix.co.il
For more information, please contact:
Dov Tamarkin, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il.
###
United States Patent No. 7,700,076, entitled “Penetrating pharmaceutical foam” covers unique emollient foam compositions and aqueous foam compositions that can be used to deliver a wide range of actives having activity against many diseases and disorders.
"Foamix continually strives to strengthen and expand its intellectual property position, which is a key aspect to our business and competitive position. The grant of this U.S. patent is the result of extensive ongoing efforts to develop a stream of innovative products and technologies for the dermatology and gynecology markets that provide enhanced efficacy and consumer satisfaction," said Dr. Dov Tamarkin, CEO of Foamix.
The patent claims foam compositions comprising urea, alpha-hydroxy acids (such as lactic acid and glycolic acid) and beta-hydroxy acids, e.g., salicylic acid, which are keratolytic).
The granted claims are further directed to foam compositions that contain skin penetration enhancers, including inter alia propylene glycol, glycerol, dimethyl isosorbide, and certain polyethylene glycol PEG polymers. The claims also cover a variety of drugs that can additionally be incorporated in such compositions, including antibacterial agents, antifungals, antiviral agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators.
About Foamix Ltd.
Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical foam and Oil Gel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the-art foams and OilGel™ formulations provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation.
To date, Foamix has twenty two issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S.
For additional information please see: www.foamix.co.il
For more information, please contact:
Dov Tamarkin, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il.
###
Contact
Foamix Ltd
Dov Tamarkin
97289316233
www.foamix.co.il
Dov Tamarkin
97289316233
www.foamix.co.il
Contact
Categories